Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Keratosis, Actinic 10Condylomata Acuminata 3Head and Neck Neoplasms 2Colorectal Neoplasms 2Warts 1Virus Diseases 1Usual Type Vulval Intraepithelial Neoplasia (uVIN) 1Urologic Neoplasms 1Urologic Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Sexually Transmitted Diseases 1Radiodermatitis 1Papillomavirus Infections 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Keratosis, Seborrheic 1Hemangioma, Cavernous 1Hemangioma 1Head and Neck Cancer Patients Treated With Radiotherapy 1Exanthema 1Dermatitis, Contact 1Carcinoma, Basal Cell 1Carcinoma 1

Interventions

ranpirnase 1VP-102 1Therapies, Investigational 1Imiquimod 1Gels 1Community Health Workers 1Cantharidin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sexually Transmitted Diseases × Gels × Clear all
NCT02724254 2018-07-20

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Twice Daily Topical Applications of AP611074 5% Gel for up to 16 Weeks in Condyloma Patients

Vaxart

Phase 2 Completed
218 enrolled

Condylomata Acuminata, Sexually Transmitted Diseases, Virus Diseases, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡